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for the flagellum’s function. Further confirmation of this theory is 
provided by Miki et al.10 through the generation of “knockout” mice 
for the sperm-specific isoenzyme of glyceraldehyde 3-phosphate 
dehydrogenase  (Gapds-/-). The authors found that sperm from 
Gapds-/- mice had impaired motility and a lower ATP concentration 
than wild-type mice even though mitochondrial respiration, evaluated 
by the rate of oxygen uptake, was not affected.
Glyceraldehyde 3-phosphate dehydrogenase is an enzyme of the 
glycolytic pathway that catalyzes the conversion of glyceraldehyde 
3-phosphate to 1,3-bisphosphoglycerate. Two isoforms of this enzyme 
exist in mammals: GAPDH, found in all somatic cells; GAPDS, found 
only in sperm. GAPDS (GAPD2 in humans) is located in the principal 
piece of the flagellum, closely bound to the fibrous sheath. Various 
studies have investigated the chemical and kinetic properties of this 
enzyme to identify any changes in the regulation of glycolysis and 
sperm motility. In contrast, there are few studies analyzing the genetic 
basis of hypokinesis. For this reason, our study investigated the GAPD2 
gene in human sperm to evaluate if asthenozoospermia was correlated 
with any changes in its expression in spermatozoa.
METHODS
Patients
The study was approved by our University Hospital’s Institutional 
Review Board. The written informed consent was obtained from all 
INTRODUCTION
Sperm produces high levels of adenosine-5’-triphosphate  (ATP), 
which is used mainly for kinetic activity. There are two much-debated 
pathways for ATP production such as mitochondrial oxidative 
phosphorylation and glycolysis. ATP is synthesized more efficiently 
by mitochondrial respiration than by the glycolytic pathway. It has 
therefore been suggested that the energy required for sperm motility 
is produced by oxidative phosphorylation while glycolysis seems to 
be an important source for ATP transmission along the flagellum.1,2
Various studies have found a positive correlation between 
mitochondrial activity and sperm motility.3,4 Mitochondria are in 
fact localized in a limited region of the sperm, so it is unlikely that 
the ATP could rapidly disperse along the flagellum by diffusion 
alone. Mathematical models based on the study of ATP diffusion and 
morphometric estimates of the volume of the mouse sperm flagellum 
revealed that the ATP produced by the mitochondria in the midpiece 
cannot provide the energy required for the entire flagellum.5 In 
rodents, for example, which have a very long flagellum, it is unlikely 
that ATP can reach the far end. For these reasons, various authors 
have suggested metabolic strategies for the production and delivery 
of ATP along the flagellum, such as ATP shuttles or ATP formation 
through glycolysis.2,6,7 The studies by Travis et  al.8 and Mukai and 
Okuno9 demonstrated that oxidative phosphorylation is not necessary 
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study participants. We studied 116 semen samples from 116 patients 
attending the Seminology Laboratory - Sperm Bank, the Department 
of Experimental Medicine, “La Sapienza” University of Rome for 
analysis of seminal fluid from 2012 to 2013. The patients had not 
been medically or surgically treated in the 3 months before the study 
and did not have any conditions (fever, etc.) that might interfere with 
the semen analysis. Semen examination and gene expression were 
performed for all patients.
Semen analysis
Semen samples were collected by masturbation after 3–5 days of 
abstinence. All samples were allowed to liquefy at 37°C for 60 min 
and were then assessed according to the World Health Organization 
guidelines  (2010).11 The following variables were taken into 
consideration: ejaculate volume (ml), sperm concentration (n × 106 ml−1), 
total sperm number (n × 106 per ejaculate), progressive motility (%), 
and morphology (% abnormal forms). In addition to raw motility data, 
absolute values in terms of millions of motile sperm per ejaculate were 
also calculated (obtained by multiplying the total sperm per ejaculate 
by the percentage of sperm motility). A sperm viability test was carried 
out to differentiate cell death from immotility by staining with eosin 
Y 0.5% in saline solution.
These samples were divided into two groups on the basis of their 
motility (WHO 2010)11 such as Group A consisted of 58 samples with 
progressive motility ≥45% (normokinetic samples) and Group B of 
58 samples with progressive motility ≤30% (hypokinetic samples).
Gene expression
GAPD2 gene expression studies were carried out on 116 semen samples 
from patients aged 16–50 years. Semen samples were diluted with 
PBS to around 10 × 106 sperm ml−1 and underwent osmotic shock to 
eliminate the nongamete cell component so as to enable the study of 
both motile and immotile sperm. Aliquots of 1 ml of the diluted samples 
were centrifuged at 1600 g 10 min, and the pellets were incubated with 
1 ml of cell lysis buffer (0.1% SDS, 0.5% Triton X-100 in distilled H2O) 
for 60 min on ice. After incubation, the absence of any round cells was 
confirmed under the optical microscope.
Total RNA was extracted from sperm using the SV Total RNA 
Isolation System RNeasy Mini Kit (PROMEGA, Madison, WI, USA) 
according to the manufacturer’s instructions. Reverse transcription 
for cDNA synthesis was carried out on 2 Pg of RNA extracted from 
each sample in a final reaction volume of 20 Pl according to the 
manufacturer’s instructions (PROMEGA, Madison, WI, USA).
Real-time PCR quantification of mRNA was carried out 
using gene expression Assay Mix containing unlabeled primers 
and TaqMan MGB fluorescent probes labeled at the 5’ end with 
6-carboxy-fluorescein  (FAM, reporter dye)  (Applied Biosystems, 
Carlsbad, CA, USA). GAPD2-specific primers and probes were used, 
and PRM2 was used as the endogenous gene for sample normalization. 
In our experience, the expression of this PRM2 gene is constant in both 
normokinetic and hypokinetic samples.
The reaction was carried out in a 25 Pl reaction volume containing 
12.5 Pl Master Mix 2X, 1.25 Pl TaqMan gene expression Assay 
Mix 20X  (Applied Biosystems, Carlsbad, CA, USA), 2.5 Pl cDNA 
10 ng Pl−1, and 8.75 Pl nuclease-free H2O. Real-time PCR amplification 
was carried out in a 48-well plate with STEP ONE  (Applied 
Biosystems, Carlsbad, CA, USA). To improve statistical reliability and 
reproducibility, each sample was loaded in triplicate onto the reaction 
plate, and the mean threshold cycle (Ct) value was considered for each 
gene. To minimize the variability due to the different efficiencies of 
the reverse transcription reactions, the quantity of GAPD2 cDNA was 
normalized to the quantity of PRM2.
Statistical analysis
Gene expression was analyzed by ''Ct (comparative Ct), where the 
first 'Ct indicates the normalization of the CT of the target gene 
versus endogenous gene whereas the second 'Ct, ''Ct, indicates 
the calibration of the target samples in comparison with the control. 
GAPD2 expression measured by real-time PCR was calculated 
comparing the samples with the control. The control sample (CTRL) 
is the mean of the 'Ct of the samples from Group A.
The Kolmogorov–Smirnov test was used to evaluate the 
distribution of the parameters (ΔCt, total motility). Data were expressed 
as mean ± standard deviation  (s.d.). The Mann–Whitney was used 
to compare normokinetic and hypokinetic samples. Spearman’s 
correlation between 'Ct and total motility and between 'Ct and 
millions of motile sperm per ejaculate was calculated.
Data were adjusted for possible confounding factors such as 
age. All statistical analyses were performed using GraphPad Prism 
version 5 (GraphPad Software Inc., La Jolla, CA, USA). A two-tailed 
P < 0.05 was considered statistically significant.
RESULTS
Table 1 shows the means and s.d.s for age in years, semen parameters, 
and sperm vitality for Groups A and B. There were statistically 
significant differences between Groups A and B for all parameters 
except semen volume. GAPD2 mRNA expression was evaluated using 
real-time PCR on normokinetic and hypokinetic samples with the 
''Ct method. Figure 1 shows the values for GAPD2 expression in 
Group B versus Group A, assuming Group A as the control, equal to 1 
(fold change 1.2 vs 1.0). The difference between the two values was not 
statistically significant. It can be seen that the expression profiles for the 
two groups are very similar. The mean 'Ct was as follows – Group A, 
5.79 ± 1.04; Group B, 5.47 ± 1.27. The Mann–Whitney analysis of the 
'Ct of the normokinetic and hypokinetic samples demonstrated that 
there was no statistically significant difference  (P = 0.19) between 
the two groups in the expression of the gene of interest for crude and 
adjusted data (Figure 2). There was no correlation between patient’s 
age and GAPD2 gene expression (r2 = 0.005; P = 0.46).
Correlation analysis revealed that GAPD2 gene expression ('Ct) 
increases with increasing motility in both Groups A and B 
although this correlation was not statistically significant (P = 0.40; 
P = 0.22) (Figure 3). There was no correlation between the millions 
of motile sperm per ejaculate and 'Ct (Figure 4).
DISCUSSION
Despite numerous studies, the molecular and biochemical events 
involved in sperm kinetics are still unknown. In all kinetics-related 
biochemical processes, ATP acts as the molecular motor which 
Figure 1: Relative GAPD2 expression in Group B versus A, assuming 
Group A (control) = 1.
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generates power for the flagellar movement. Glycolysis seems to be 
an important source for delivering ATP along the entire flagellum.1 
Westhoff and Kamp12 and Welch et  al.13 found that glyceraldehyde 
3-phosphate dehydrogenase, the NAD-dependent glycolytic enzyme 
that catalyzes the transformation of glyceraldehyde 3-phosphate (GAP) 
to 1,3-biphosphoglycerate  (1,3 BPG), is bound in large quantities 
to the fibrous sheath of the sperm of various mammals, including 
humans. In 2004, Mukai and Okuno9 demonstrated that sperm 
incubated with mitochondrial respiration inhibitors (carbonyl cyanide 
m-chlorophenylhydrazone and antimycin A) showed a high beat 
frequency in the presence of glucose while the same sperm did not 
retain their motility with pyruvate or lactate, thus indicating that the 
ATP produced by the glycolytic process was sufficient for flagellar 
movement. The length of the flagellar structure of mammalian sperm 
impedes ATP diffusion from the mitochondria in the midpiece to the 
principal piece and endpiece, which together account for the majority 
of its structure. For this reason, special catalytic isoenzymes could be 
the result of a reorganization of the metabolism guided by a structural 
modification.14 The localization of these enzymes in the fibrous sheaths 
thus enables the local production of ATP in proximity with the dynein’s 
ATPase along the entire axoneme to the end of the flagellum. It also 
enables the enzymes to function correctly despite the mechanical 
perturbations taking place during the flagellar beat.
In sperm, various factors coincide to create a high throughput 
ATP production system, namely large cell surface in relation to 
the small volume, abundance of glycolytic enzymes bound to the 
fibrous sheaths, and ATP use by the ATPase in the dyneins, enabling 
the reactions to take place in a forward direction.15 Glycolysis thus 
seems to have an important role in energy production. Evidence 
of this theory comes from studies of GAPD2 by Elkina et al.16 who 
demonstrated an enzyme activity 2.5–3  times lower in hypokinetic 
samples than in normokinetic samples while tissue localization studies17 
revealed GAPD2 in the testicles and epididymis. In both human and 
rat testicles, this enzyme was present mainly in the cytoplasm of all 
spermatogenic cells while, in the epididymis, it was found in the 
sperm tail. Liu et al. study17 also demonstrated the localization of the 
glycolytic enzyme in the principal piece of the sperm flagellum and 
the ability of anti-GAPD2 antibodies to inhibit sperm motility and 
penetration into the zona pellucida. A very recent study by Takei et al.18 
investigated the correlation between the glycolytic metabolic pathway 
and flagellar movement in mouse sperm though analysis of motility 
in relation to beat cross frequency, bend angle, sliding velocity, and 
local bending. The results of that study revealed that in the presence of 
substrates of mitochondrial respiration and glycolysis inhibitors, there 
is a reduction in ATP concentration and kinetic parameters, especially 
in the distal part of the flagellum. In humans, the sperm isoenzyme 
glyceraldehyde 3-phosphate dehydrogenase is coded by a GAPD2 
paralogs gene, located in chromosome 19q13.12, which contains 
11 exons. The length of the primary transcript of this gene is 11 908 
nucleotides, and it produces a protein of 408 amino acid residues. The 
sperm isoenzyme differs from the somatic isoenzyme in that it has 73 
residues constituting the N-terminal region, rich in proline, which is 
needed to bind the fibrous sheaths.
Studies in mice found that Gapds mRNA is initially found in round 
spermatids, reaches its peak levels in condensed spermatids but is only 
found later in elongated spermatids,19,20 suggesting late gene expression. 
In fact, Mezquita et al.21 identified alternative transcription initiation 
in chicken testes characterized by alternative splicing in 5’ regions 
of the pre-mRNA, resulting in at least six different types of mRNAs 
and polyadenylation; all these processes could underlie the various 
mechanisms for the regulation of Gapds expression.
The presence of Gapds mRNA in the first stages of spermatogenesis 
and evidence of the enzyme only in later stages also indicates that the 
translation is controlled by specific mechanisms identified in transline 
protein or TB RBP (testis brain RNA-binding protein), i.e., proteins 
that bind DNA or RNA, carrying out different functions. In vitro, 
mouse transline proteins form a Gapds mRNA complex, necessary for 
the incorporation of the GAPDS protein in the fibrous sheaths during 
growth.22 In fact, germ cells use mRNA storage and delayed translation 
Table 1: Means and standard deviations for age in years, semen parameters, and sperm vitality for Groups A and B
Age (year) Volume (ml) Sperm concentration (n×106 ml) Total sperm number (n×106) Progressive motility (%) Abnormal forms (%) Viability (%)
Group A 29.84±6.54 3.45±1.48 103.60±38.06 345.50±158.20 55.26±4.02 73.43±3.15 80.67±2.85
Group B 34.59±7.47 3.38±1.75 35.41±30.85 104.70±90.81 19.22±7.53 89.95±4.82 47.53±13.09
P <0.001 0.56 <0.001 <0.001 <0.001 <0.001 <0.001
Figure 2: GAPD2 expression in Groups A and B.
Figure 3: 'Ct versus progressive motility in Groups A and B.
Figure 4: Absolute values in terms of millions of motile sperm per ejaculate 
versus 'Ct in Groups A and B.
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mechanism after the chromatin has already been packaged. Sperm not 
only contains haploid genetic information but also has an abundance 
of transcripts, thought to be remnants of mRNA which represent a 
genetic fingerprint and can be considered a historic record of gene 
expression during spermatogenesis. It is thus possible that errors during 
the spermatogenetic process are encapsulated within the repository of 
spermatozoal RNA.23
Sperm from fertile and infertile men have different quantities 
of transcripts,24,25 and some studies have found different gene 
expressions to be correlated with different sperm concentrations, 
percentage motility and morphology.26 Research on gene expression 
could, therefore, provide significant information on physiological or 
pathological processes. Specifically, GAPD2 gene expression could be 
a good marker for the analysis of spermatogenesis as its transcription 
and translation products are temporarily separated and form a complex 
with RNA binding protein, which induces the translation and delays 
mRNA degradation. This was demonstrated by Dorosh et al.27 through 
analysis of the expression of the spermatogenesis-related genes MND1, 
SPATA22, GAPD2, and ACR in 47 testicular biopsies of men with 
nonobstructive azoospermia. The aim of that study was to identify 
markers predictive of sperm recovery in such patients. It found a low 
level of GAPD2 transcripts in these patients, suggesting that changes to 
the profile of this gene were associated with impaired spermatogenesis. 
In contrast, Shen et  al.28 evaluated gene and protein expression in 
selected sperm from 30 asthenozoospermic semen samples, with 30 
normozoospermic samples used as the control. The proteome study 
found 15 new proteins expressed at different levels in the cases in 
comparison with the controls, including the GAPD2 enzyme. The 
authors carried out a quantitative RT PCR analysis to compare the 
transcript and protein levels, finding no correlation between gene 
expression and protein expression. Asthenozoospermic samples 
showed lower GAPD2 gene expression than normozoospermic samples, 
but the transcriptional level was not correlated with the protein level. 
The noncorrespondence between gene transcription and protein 
translation seems to be the result of a complex network of factors 
which interact under given conditions to determine a pathological 
phenotype. Therefore, the role played by GAPD2 in sperm motility 
currently remains unknown.
No variability in gene expression associated with sperm motility 
was found in our study. There was no difference in the GAPD2 gene 
expression profile between normozoospermic and hypokinetic samples, 
indicating that transcription occurs normally in these two semen 
phenotypes. A correlation analysis of our data found that GAPD2 gene 
expression ('Ct) rises with increasing total motility in both normo 
and hypokinetic samples although this correlation was not statistically 
significant. Furthermore, no correlation was found between millions 
of motile sperm per ejaculate and 'Ct. The latter finding is very 
interesting as it suggests that hypomotility may be due to a possible 
posttranscriptional impairment of the control mechanism, such as 
mRNA splicing, or posttranslational changes, such as phosphorylation, 
glycosylation, cutting, and posttranslational splicing.
These protein structural changes may provide the basis for 
diverse functional activities such as the potential role of GAPD2 
in sperm/oocyte binding. A  recent study, in fact, found GAPD2 
localization in the apical part of the sperm head in addition to the 
principal piece of the flagellum.29 A posttranscriptional regulation 
of gene expression, possibly related to the generation of piRNAs, 
could also be postulated.30 Furthermore, glyceraldehyde 3-phosphate 
dehydrogenase regulates the glycolytic process and seems to be the 
target of compounds that impair male fertility.31 This could also suggest 
that environmental factors might influence the chemical and kinetic 
properties of this enzyme.
One limitation of our study is that we do not know the protein 
expression levels. It would be interesting to perform a proteomic 
study to understand the relationship between hypokinesia and sperm 
protein levels. However, the study also has some strengths: awareness 
of GAPD2 expression levels in given semen phenotypes adds to our 
knowledge of molecular sperm energy production and enables us 
to theorize that changes to the mechanisms of posttranscriptional 
regulation of mRNA or translational changes may be the basis for 
impaired kinetics.
CONCLUSION
This study shows that there are no differences in GAPD2 expression 
between human sperm samples with impaired motility and samples 
with normal kinetics. This could suggest that GAPD2 has a minor role 
in sperm motility and demonstrates the need to continue research into 
protein expression and function. The study of posttranscriptional and 
translational changes could be an interesting aspect in the evaluation 
of the molecular pathways of sperm motility and the identification of 
clinical targets for therapeutic treatment.
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